Every material Form 8-K GoodRx Holdings, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
GoodRx said its financial statements for the quarters ended March 31 and June 30, 2026 should no longer be relied upon because Pharma Direct revenue was understated, and that prior reports on those periods should also not be relied upon. The corrected figures are higher, but the company expects to report material weaknesses in internal control over financial reporting, and the restatement remains preliminary.
Six-month total revenue to June 30, 2026 would rise from $394.4 million to $424.2 million.
Six-month net income would rise from $9.7 million to $24.6 million, and diluted EPS from $0.03 to $0.07.
The company expects to report one or more material weaknesses in internal control over financial reporting for each affected period.
The company plans to file amended Forms 10-Q for the affected periods as soon as practicable.
GoodRx said CFO and Treasurer Christopher McGinnis will transition out of the role effective 11:59 p.m. Eastern on August 5, 2026, and that his departure is not due to any disagreement with the company. Chief Strategy & Operations Officer Justin Fengler will also become CFO & Treasurer and principal financial officer effective August 6, 2026, while continuing to oversee strategy and operations.
Christopher McGinnis leaves the CFO & Treasurer role effective 11:59 p.m. ET on August 5, 2026; the filing says the exit is not tied to any disagreement on operating performance, financial reporting or accounting.
Justin Fengler, 38, has been Chief Strategy & Operations Officer since September 2025 and with GoodRx since 2016; he takes over as CFO & Treasurer on August 6, 2026.
Fengler's compensation includes restricted stock units and performance stock units each valued at $600,000, plus a one-time $100,000 cash payment.
McGinnis expects to receive Tier I Executive Severance Plan benefits under a separation agreement the company has not yet signed.
GoodRx reported second-quarter 2026 revenue of $200.4 million, down 1% from $203.1 million, and net income of $8.5 million, down from $12.8 million. The company raised its full-year 2026 revenue guidance to $790 million to $805 million and its Adjusted EBITDA guidance to $240 million to $250 million, citing Pharma Direct and subscription growth.
Revenue was $200.4 million versus $203.1 million; net income was $8.5 million versus $12.8 million, and net income margin was 4.3% versus 6.3%.
Prescription transactions revenue fell 26% to $106.4 million, while Pharma Direct revenue rose 76% to $61.6 million and subscription revenue rose 39% to $28.5 million.
Adjusted EBITDA was $63.7 million versus $69.4 million, and net cash from operating activities was $80.8 million versus $49.6 million.
Full-year 2026 guidance: revenue of $790 million to $805 million and Adjusted EBITDA of $240 million to $250 million, compared with FY 2025 revenue of $796.9 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GoodRx Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →